Lexicon Pharmaceuticals I... (LXRX)
Lexicon Pharmaceuticals Statistics
Share Statistics
Lexicon Pharmaceuticals has 361.49M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 361.49M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 82.34% |
| Shares Floating | 179.54M |
| Failed to Deliver (FTD) Shares | 422.92K |
| FTD / Avg. Volume | 2.76% |
Short Selling Information
The latest short interest is 43.88M, so 12.14% of the outstanding shares have been sold short.
| Short Interest | 43.88M |
| Short % of Shares Out | 12.14% |
| Short % of Float | 26.92% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.18 and the forward PE ratio is -1.82. Lexicon Pharmaceuticals's PEG ratio is 0.06.
| PE Ratio | -1.18 |
| Forward PE | -1.82 |
| PS Ratio | 7.6 |
| Forward PS | 1.1 |
| PB Ratio | 1.62 |
| P/FCF Ratio | -1.31 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lexicon Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.44, with a Debt / Equity ratio of 0.74.
| Current Ratio | 5.44 |
| Quick Ratio | 5.44 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | -0.59 |
| Debt / FCF | -0.6 |
| Interest Coverage | -12.65 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $301.76K |
| Profits Per Employee | $-1.95M |
| Employee Count | 103 |
| Asset Turnover | 0.1 |
| Inventory Turnover | 2.67 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -66.67% in the last 52 weeks. The beta is 1.03, so Lexicon Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.03 |
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 59.6 |
| Average Volume (20 Days) | 15.33M |
Income Statement
In the last 12 months, Lexicon Pharmaceuticals had revenue of 31.08M and earned -200.4M in profits. Earnings per share was -0.63.
| Revenue | 31.08M |
| Gross Profit | 30.46M |
| Operating Income | -197.12M |
| Net Income | -200.4M |
| EBITDA | -184.29M |
| EBIT | -184.82M |
| Earnings Per Share (EPS) | -0.63 |
Balance Sheet
The company has 66.66M in cash and 108.4M in debt, giving a net cash position of -41.74M.
| Cash & Cash Equivalents | 66.66M |
| Total Debt | 108.4M |
| Net Cash | -41.74M |
| Retained Earnings | -1.97B |
| Total Assets | 298.42M |
| Working Capital | 200.94M |
Cash Flow
In the last 12 months, operating cash flow was -178.78M and capital expenditures -1.03M, giving a free cash flow of -179.81M.
| Operating Cash Flow | -178.78M |
| Capital Expenditures | -1.03M |
| Free Cash Flow | -179.81M |
| FCF Per Share | -0.56 |
Margins
Gross margin is 98.02%, with operating and profit margins of -634.2% and -644.78%.
| Gross Margin | 98.02% |
| Operating Margin | -634.2% |
| Pretax Margin | -644.78% |
| Profit Margin | -644.78% |
| EBITDA Margin | -592.93% |
| EBIT Margin | -634.2% |
| FCF Margin | -578.52% |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LXRX is $4, which is 601.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $4 |
| Price Target Difference | 601.8% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Stock Splits
The last stock split was on May 21, 2015. It was a backward split with a ratio of 1:7.
| Last Split Date | May 21, 2015 |
| Split Type | backward |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | -9.65 |
| Piotroski F-Score | 3 |